TCW Group Inc. cut its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 650,760 shares of the biopharmaceutical company’s stock after selling 57,361 shares during the quarter. TCW Group Inc. owned approximately 0.29% of Alexion Pharmaceuticals worth $77,824,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Ameriprise Financial Inc. lifted its holdings in shares of Alexion Pharmaceuticals by 3.5% during the third quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after acquiring an additional 215,005 shares during the period. Jennison Associates LLC lifted its holdings in shares of Alexion Pharmaceuticals by 720.0% during the third quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after acquiring an additional 4,682,336 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Alexion Pharmaceuticals by 10.3% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after buying an additional 174,606 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Alexion Pharmaceuticals by 32.7% in the third quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after buying an additional 383,713 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Alexion Pharmaceuticals by 21.4% in the fourth quarter. Bank of Montreal Can now owns 1,521,834 shares of the biopharmaceutical company’s stock valued at $181,998,000 after buying an additional 268,053 shares in the last quarter. 95.38% of the stock is owned by institutional investors.
In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 3,363 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $115.70, for a total transaction of $389,099.10. Following the transaction, the executive vice president now owns 71,400 shares in the company, valued at $8,260,980. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Heidi L. Wagner sold 698 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $119.35, for a total value of $83,306.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,253 shares of company stock worth $3,656,229. Company insiders own 4.35% of the company’s stock.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $121.08 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $26,840.00, a PE ratio of 55.80, a P/E/G ratio of 1.18 and a beta of 1.13. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the business earned $1.26 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.
A number of analysts have recently weighed in on ALXN shares. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Citigroup lowered their target price on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research note on Friday, February 9th. SunTrust Banks set a $172.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, February 12th. ValuEngine lowered Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Finally, Stifel Nicolaus restated a “buy” rating and issued a $151.00 target price on shares of Alexion Pharmaceuticals in a research note on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $154.64.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://ledgergazette.com/2018/03/14/alexion-pharmaceuticals-inc-alxn-shares-sold-by-tcw-group-inc-2.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.